BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma Clinical Trials

Biosyngen has obtained FDA IND clearance of BRG01 for Phase I/II clinical trials against Nasopharyngeal Cancer

Prior to this approval from the US FDA, Biosyngen's BRG01 was granted IND by China CDE on December 14th, 2022. In addition, China CDE has acknowledged...

February 18, 2023 | News

Boan Biotech's Investigational Long-acting Anti-IL-4Rα Antibody BA2101 Administered for First Patient in Phase I Clinical Trial

BA2101 is the first long-acting anti-IL-4Rα monoclonal antibody that enters the clinical trial stage in the country. It is intended to be used for tr...

February 16, 2023 | News

Boan Biotech's Investigational Anti-CD25 Antibody BA1106 Administered for First Patient in Phase I Clinical Trial

BA1106 is the first investigational anti-CD25 antibody to start clinical trials in China for treating solid tumors. Focusing on key therapeutic a...

February 13, 2023 | News

Galapagos announces topline results from Phase 3 DIVERSITY trial of filgotinib in Crohn’s disease

The two induction cohorts missed the co-primary endpoints of clinical remission and endoscopic response at Week 10 In the maintenance phase, filgotinib ...

February 09, 2023 | News

Nectin Therapeutics to Collaborate with Merck on a Clinical Trial of Anti-PVR Antibody NTX1088

Nectin Therapeutics Ltd. (Nectin), a biotechnology company developing novel targeted immunotherapies that address resistance to approved immune oncology tr...

February 08, 2023 | News

Beyond Traditional Placebo Controls in Rare Disease Clinical Trials

The Collaborative Trajectory Analysis Project (cTAP), a global coalition in rare disease, has announced evidence to support patient-centric alternativ...

February 08, 2023 | News

Amjevita™ (Adalimumab-atto), First Biosimilar to Humira®, Now Available in the United States

Amgen (NASDAQ:AMGN) announced AMJEVITA™ (adalimumab-atto), a biosimilar to Humira®* (adalimumab), is now available in the Un...

February 01, 2023 | News

TransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-RIGA, in Melanoma

TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today repor...

February 01, 2023 | News

Zhongchao Inc. Announces Introduction of Indian Anti-influenza Drugs to China

Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services to patients with oncology and ...

February 01, 2023 | News

Moderna Granted FDA Breakthrough Therapy Designation for Mrna-1345, an Investigational Respiratory Syncytial Virus (Rsv) Vaccine Candidate

 Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced mRNA-1345, an investig...

January 30, 2023 | News

Thermo Fisher Scientific Launches CE-IVD Marked Assay to Detect Treatment-Resistant Strains of HIV-1

Data derived from the test can help to serve as a critical tool to monitor and help treat HIV-1-infected individuals, as well as inform epidemiologic and g...

January 23, 2023 | News

Dr. Reddy’s successfully completes full set of clinical studies of its rituximab biosimilar for filing in the U.S., Europe

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; hereafter referred to as “Dr. Reddy’s”), a g...

January 23, 2023 | News

First Patient Dosed in CANbridge Pharmaceuticals CAN103 Phase 2 Trial for the Treatment of Gaucher Disease in China

Gaucher disease (GD), one of the most common lysosomal storage disorders, is caused by a genetic enzyme deficiency leading to an accumulation of the sphing...

January 20, 2023 | News

HighTide Therapeutics Announces First Patient Dosed in Phase 2b Clinical Study Evaluating HTD1801 in NASH (the CENTRICITY study)

This double-blind, randomized, placebo-controlled, multicentre Phase 2b study will evaluate the effect of HTD1801, 1250 mg twice daily (BID), compared to p...

January 11, 2023 | News

Stay Connected